Serotonin reuptake inhibitor provoked recurrence of alcohol hallucinosis - Remission with additive amisulpride medication: A case report

Pharmacopsychiatry

Volumn 37, Issue 2, 2004, Pages 90-92

  Hermann, D ^a   Heinz, A ^b   Croissant, B ^a   Mann, K ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; BENPERIDOL; CLOZAPINE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ALCOHOL HALLUCINOSIS; ALCOHOLISM; ANHEDONIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HALLUCINOSIS; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RECURRENT DISEASE; REMISSION; SIDE EFFECT; TREATMENT OUTCOME;

ALCOHOL WITHDRAWAL DELIRIUM; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RISPERIDONE; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SULPIRIDE;

EID: 2442560048     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-815532     Document Type: Article

References (19)

1. Chong SA, Tan CH, Lee HS. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. J Clin Psychopharmacol 1997; 17: 68-69
2. Croissant B, Hermann D, Olbrich R. Einspareffekte bei der Clozapin-Dosierung. Psychopharmakotherapie 2001; 8: 128-130
3. Glass IB. Alcohol hallucinosis: a psychiatric enigma - 2. Follow-up studies. Br J Addict 1989; 84: 151-64
4. Koe BK, Weisman A, Welch WM, Brown RG. Sertraline, 1S, 4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthyline, a new uptake inhibitor with selectivity for serotonin. J Pharamcol Exp Ther 1983; 230: 94-102
5. Mann K, Bartels M, Bauer H. Amisulpride - An open clinical study of a new benzamide in schizophrenic patients. Pharmacopsychiatry 1984; 17: 111-115
6. Martin P, Waters N, Schmidt CJ, Carlsson A, Carlsson ML. Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone. J Neural Transm 1998; 105: 365-396
7. Neiman J, Litton JE. Reduced [11C]flumazenil radioligand binding in the thalamus in alcoholics. Addict Biol 2000; 5: 97-99
8. Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HAT2A receptor occupancy in schizophrenic patients. Am J Psychiat 1999; 156: 869-875
9. Popli AP, Fuller MA, Jaskiw GE. Sertraline and psychotic symptoms: A case series. Ann Clin Psychiat 1997; 9: 15-17
10. Schmidt CJ, Sorensen SM, Kenne JH, Carr AA, Palfreyman MG. The role of 5-HT2A receptors in antipsychotic activity. Life Sci 1995; 56: 2209-2222
11. Silver H, Jahjah N, Kushnir M. Psychotic symptoms in schizophrenics during chronic fluvoxamine treatement. A report of two cases. Schizophr Res 1995; 16: 77-79
12. Soyka M, Wegner U, Moeller HJ. Risperidone in treatment-refractory chronic alcohol hallucinosis. Pharmacopsychiatry 1997; 30: 35-136
13. Soyka M. Alcohol-induced hallucinosis. Clinical aspects, pathophysiology and therapy. Nervenarzt 1996; 67: 891-895
14. Soyka M, Dresel S, Horak M, Rüther T, Tatsch K. PET and SPECT findings in alcohol hallucinosis: case report and super-brief review of the pathophysiology of this syndrome. W J Biol Psychiat 2000; 1: 215-218
15. Sproule BA, Otton SV, Cheung SW, Zhong XH, Romach MK, Seller EM. CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol 1997; 17: 102-106
16. Surawicz FG. Alcohol hallucinosis: a missed diagnosis. Can J Psychiat 1980; 25: 57-63
17. Tsuang JW, Irwin MR, Smith TL, Schuckit MA. Characteristics of men with alcoholic hallucinosis. Addiction 1994; 89: 3-78
18. Wiesbeck GA, Weijers HG, Lesch OM, Glaser T, Toennes PJ, Boening J. Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol 2001; 36: 29-334
19. Yasui-Furkori N, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G. Different enantioselective 9-hydroxylation of risperidone by two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001; 29: 1263-1268